Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2019

View Archived Issues

Parkinson's drug inhibits obesity gene

Novel mouse model of human acute myeloid leukemia with autologous immune system

Researchers create animal model of orthopedic injury-induced hypercoagulability

Identification of selective, orally active RORgammat inverse agonists

Positive initial phase II data for nomacopan in bullous pemphigoid

Tracon Pharmaceuticals initiates phase I study of TJ-004309 in combination with atezolizumab

New blood test developed for early Alzheimer's diagnosis

Yuhan presents preclinical data for its novel anti-TIGIT antibody, YH-29143

Sunshine Lake Pharma divulges 5-HT1A receptor agonists

Nanjing TransThera Biosciences patents PDE9 inhibitors

Preclinical characterization of humanized anti-MERTK monoclonal antibody, RGX-019

MGL inhibitors revealed in Takeda Pharmaceutical patent

Phase I data reported for RO-7049389 in patients with chronic HBV infection

MET-409 is safe and well tolerated in phase I study in healthy male subjects

Beijing Yuezhikangtai Biomedicines identifies hedgehog-signaling inhibitors

Fujifilm presents new antibacterials

Preclinical characterization detailed for phase I cancer candidate S-64315/MIK-665

Takeda communicates data on ART-648 in preclinical models of NASH

Innovent begins phase I trial of PD-1/PD-L1 bispecific antibody IBI-318

Teva discontinues development of fremanezumab for cluster headaches

Tiziana's phase IIa trial of milciclib in advanced liver cancer passes interim safety review

FDA approves Skyrizi for moderate to severe plaque psoriasis

MET/SRC/CSF-1R inhibitor TPX-0022 shows antitumor activity, IND planned

TC BioPharm conducting phase I study of TCB-002 in AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...